Literature DB >> 22589443

Effects of palmitoylethanolamide on aqueous humor outflow.

Akhilesh Kumar1, Zhuanhong Qiao, Pritesh Kumar, Zhao-Hui Song.   

Abstract

PURPOSE: To study the effects of palmitoylethanolamide (PEA), a fatty acid ethanolamide, on aqueous humor outflow facility.
METHODS: The effects of PEA on outflow facility were measured using a porcine anterior segment-perfused organ culture model. The involvements of different receptors in PEA-induced changes were investigated using receptor antagonists and adenovirus delivered small hairpin RNAs (shRNAs). PEA-induced activation of p42/44 mitogen-activated protein kinase (MAPK) was determined by Western blot analysis using an antiphospho p42/44 MAPK antibody.
RESULTS: PEA caused a concentration-dependent enhancement of outflow facility, with the maximum effect (151.08 ± 11.12% of basal outflow facility) achieved at 30 nM of PEA. Pretreatment of anterior segments with 1 μM cannabinoid receptor 2 antagonist SR144528 and 1 μM PPARα antagonist GW6471, but not 1 μM cannabinoid receptor 1 antagonist SR141716A, produced a partial antagonism on the PEA-induced increase of outflow facility. Treatment of TM cells with PEA for 10 minutes activated phosphorylation of p42/44 MAPK, which was blocked by pretreatment with SR1444528 and GW6471, but not SR141716A. Knocking down the expression of either GPR55 or PPARα receptors with specific shRNAs for these receptors partially blocked PEA-induced increase in outflow facility and abolished PEA-induced phosphorylation of p42/44 MAPK. PD98059, an inhibitor of the p42/44 MAPK pathway, blocked both PEA-induced enhancement of aqueous humor outflow facility and PEA-induced phosphorylation of p42/44 MAPK.
CONCLUSIONS: Our results demonstrate that PEA increases aqueous humor outflow through the TM pathway and these effects are mediated by GPR55 and PPARα receptors through activation of p42/44 MAPK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589443      PMCID: PMC4625824          DOI: 10.1167/iovs.11-9294

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  46 in total

1.  FATTY ACID AMIDES OF ETHANOLAMINE IN MAMMALIAN TISSUES.

Authors:  N R BACHUR; K MASEK; K L MELMON; S UDENFRIEND
Journal:  J Biol Chem       Date:  1965-03       Impact factor: 5.157

Review 2.  Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling.

Authors:  Olivia S Gardner; Brian J Dewar; Lee M Graves
Journal:  Mol Pharmacol       Date:  2005-07-14       Impact factor: 4.436

Review 3.  The search for the palmitoylethanolamide receptor.

Authors:  Jesse LoVerme; Giovanna La Rana; Roberto Russo; Antonio Calignano; Daniele Piomelli
Journal:  Life Sci       Date:  2005-08-19       Impact factor: 5.037

4.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; J Millan; J M Derocq; P Casellas; C Congy; D Oustric; M Sarran; M Bouaboula; B Calandra; M Portier; D Shire; J C Brelière; G L Le Fur
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

5.  Ocular activity of topically administered anandamide in the rabbit.

Authors:  Y Mikawa; S Matsuda; T Kanagawa; T Tajika; N Ueda; Y Mimura
Journal:  Jpn J Ophthalmol       Date:  1997 Jul-Aug       Impact factor: 2.447

6.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

7.  The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.

Authors:  S I Jaggar; F S Hasnie; S Sellaturay; A S Rice
Journal:  Pain       Date:  1998-05       Impact factor: 6.961

8.  Human trabecular cells. I. Establishment in tissue culture and growth characteristics.

Authors:  J R Polansky; R N Weinreb; J D Baxter; J Alvarado
Journal:  Invest Ophthalmol Vis Sci       Date:  1979-10       Impact factor: 4.799

9.  Endocannabinoids protect the rat isolated heart against ischaemia.

Authors:  Philippe Lépicier; Jean-François Bouchard; Caroline Lagneux; Daniel Lamontagne
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

10.  Involvement of the Erk-MAP kinase pathway in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs.

Authors:  J Preston Alexander; Ted S Acott
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-01       Impact factor: 4.799

View more
  6 in total

Review 1.  A Proteomic View of Cellular and Molecular Effects of Cannabis.

Authors:  Morteza Abyadeh; Vivek Gupta; Joao A Paulo; Veer Gupta; Nitin Chitranshi; Angela Godinez; Danit Saks; Mafruha Hasan; Ardeshir Amirkhani; Matthew McKay; Ghasem H Salekdeh; Paul A Haynes; Stuart L Graham; Mehdi Mirzaei
Journal:  Biomolecules       Date:  2021-09-27

Review 2.  An update on PPAR activation by cannabinoids.

Authors:  Saoirse Elizabeth O'Sullivan
Journal:  Br J Pharmacol       Date:  2016-05-19       Impact factor: 8.739

3.  Role of GPR55 during Axon Growth and Target Innervation.

Authors:  Hosni Cherif; Anteneh Argaw; Bruno Cécyre; Alex Bouchard; Jonathan Gagnon; Pasha Javadi; Sébastien Desgent; Ken Mackie; Jean-François Bouchard
Journal:  eNeuro       Date:  2015-11-09

4.  Rod photoreceptors express GPR55 in the adult vervet monkey retina.

Authors:  Joseph Bouskila; Pasha Javadi; Christian Casanova; Maurice Ptito; Jean-François Bouchard
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

Review 5.  The Endocannabinoid System as a Therapeutic Target in Glaucoma.

Authors:  Elizabeth A Cairns; William H Baldridge; Melanie E M Kelly
Journal:  Neural Plast       Date:  2016-01-12       Impact factor: 3.599

Review 6.  Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy.

Authors:  Jan M Keppel Hesselink; Ciro Costagliola; Josiane Fakhry; David J Kopsky
Journal:  J Ophthalmol       Date:  2015-11-18       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.